Navigation Links
Pradaxa® (dabigatran etexilate mesylate) Capsules Now on Formulary at Nation's Top Heart Hospitals
Date:7/21/2011

were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and GI ulcer).  Drug hypersensitivity reactions were reported in <0.1% of patients receiving PRADAXA.

Other Measures Evaluated

The risk of myocardial infarction was numerically greater in patients who received PRADAXA 150 mg than in those who received warfarin.  

For full PRADAXA prescribing information and medication guide, please visit www.pradaxa.com or contact Boehringer Ingelheim's Drug Information Unit at 1-800-542-6257.

About the Boehringer Ingelheim Cares Foundation Patient Assistance Programs

For more than 125 years, Boehringer Ingelheim has been focused on improving the lives of patients. In keeping with the company commitment to do the most good for the most people, Boehringer Ingelheim works hard to ensure its medicines are accessible to everyone who needs them, including senior citizens and families on limited incomes. The Boehringer Ingelheim Cares Foundation Patient Assistance Programs (BI-PAP) make Boehringer Ingelheim medicines available free of charge to patients who are without pharmaceutical insurance coverage, and who meet certain household income levels.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-ow
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE)
2. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
3. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
4. Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
5. Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
6. Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
7. FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
8. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
9. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
10. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
11. Roxane Laboratories, Inc. Announces the Launch of Mycophenolate Mofetil 250mg Capsules and 500mg Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
(Date:1/14/2014)... January 14, 2014 Carahsoft and CDS ... January 23, 2014 at 2pm EST (11am PST), “Natural ... topic focuses on how technology can turn raw, heterogeneous ... for government agencies. The online webinar will last approximately ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest international ... medicinal plants and therapeutic derivatives thereof has endorsed ... and researchers about the challenges of adulterated herb ... ) The Society for Medicinal ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... QUEBEC CITY, Aug. 31 /PRNewswire-FirstCall/ - Medicago Inc. ... developing highly effective and affordable vaccines based on ... announced that it was included in a report ... and Technology entitled "Report to the President on ...
... Dedicated to Medical... -- ROME, August 31, 2010 ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
... 30 Uckele Health & Nutrition is honored to ... 500/5000 list of the fastest-growing, private companies in America. ... enterprises who have appeared on the list multiple times, ... The list represents the most comprehensive look at the ...
Cached Biology Technology:Medicago named in Presidential report on meeting the challenges of pandemic influenza 2Medicago named in Presidential report on meeting the challenges of pandemic influenza 3Medicago named in Presidential report on meeting the challenges of pandemic influenza 4Serono Symposia International Foundation (SSIF) Launches a New Web Site Dedicated to Medical Education on Phenylketonuria (PKU) 2Serono Symposia International Foundation (SSIF) Launches a New Web Site Dedicated to Medical Education on Phenylketonuria (PKU) 3Serono Symposia International Foundation (SSIF) Launches a New Web Site Dedicated to Medical Education on Phenylketonuria (PKU) 4Serono Symposia International Foundation (SSIF) Launches a New Web Site Dedicated to Medical Education on Phenylketonuria (PKU) 5Serono Symposia International Foundation (SSIF) Launches a New Web Site Dedicated to Medical Education on Phenylketonuria (PKU) 6Serono Symposia International Foundation (SSIF) Launches a New Web Site Dedicated to Medical Education on Phenylketonuria (PKU) 7Serono Symposia International Foundation (SSIF) Launches a New Web Site Dedicated to Medical Education on Phenylketonuria (PKU) 8Uckele Health & Nutrition Ranks on the 2010 Inc. 5000 List 2
(Date:4/17/2014)... to treat tuberculosis could be the basis for a ... fungal infections and parasites, yet evade resistance, according to ... , Led by U. of I. chemistry professor Eric ... SQ109 attacks the tuberculosis bacterium, how the drug can ... malaria and how targeting multiple pathways reduces the ...
(Date:4/17/2014)... development of stem cell therapies to cure a variety ... cell populations based on cell surface markers. Researchers from ... that is highly expressed in a type of stem ... describe in an article in BioResearch Open Access ... publishers. The article is available free on the ...
(Date:4/17/2014)... Professor Marc Andr Gauthier and Professor Luca Razzari ... each been awarded large grants from the John ... for Innovation (CFI) for the acquisition of state-of-the-art ... be added matching grants from the Ministre de ... et de la Technologie (MESRST). These new laboratories ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2New state-of-the-art biotech and nanotech equipment for INRS 2
... the first time in its history, the American Society for ... session of the ASCB,s Annual Meeting, for "An Evening of ... on Saturday, Dec. 15. Members of the public ... will receive complimentary registration to the ASCB keynote addresses by ...
... Human Development in Berlin have shown that synchronization emerges ... musicians play different voices. In a study published November ... and her team used electrodes to record the brain ... the same duet. The results point to brain synchronicity ...
... on developing wheat varieties with higher yields and enhanced ... have teamed up with scientists at nine other institutions ... Results from that endeavor, led by researchers at the ... reported Nov. 29 in the journal Nature . ...
Cached Biology News:Public invited to 'An Evening of Science & Art' at ASCB Annual Meeting 2Musical duets lock brains as well as rhythms 2UC Davis researchers aid effort to sequence the complex wheat genome 2